Effectiveness and safety of 18F-FDG PET in the evaluation of dementia: A review of the recent literature

Journal of Nuclear Medicine

Volumn 53, Issue 1, 2012, Pages 59-71

  Bohnen, Nicolaas I ^a,b,c   Djang, David S W ^d   Herholz, Karl ^e   Anzai, Yoshimi ^f,g   Minoshima, Satoshi ^f  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^d SWEDISH MEDICAL CENTER   (United States)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Alzheimer disease; Dementia; Diagnosis; Fluorodeoxyglucose; PET; Physician confidence; Prognosis

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT;

ALZHEIMER DISEASE; CASE CONTROL STUDY; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED DIAGNOSIS; DEMENTIA; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; FRONTOTEMPORAL DEMENTIA; GLUCOSE METABOLISM; GOLD STANDARD; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; INTERMETHOD COMPARISON; MILD COGNITIVE IMPAIRMENT; PATIENT SAFETY; PHYSICIAN ATTITUDE; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; SENSITIVITY AND SPECIFICITY; METABOLISM; METHODOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; SAFETY; SCINTISCANNING; STANDARD;

ALZHEIMER DISEASE; DEMENTIA; FLUORODEOXYGLUCOSE F18; HUMANS; POSITRON-EMISSION TOMOGRAPHY; REFERENCE STANDARDS; SAFETY;

EID: 84855364400     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.096578     Document Type: Review

References (95)

1. Kung HC, Hoyert DL, Xu J, Murphy SL. Deaths: final data for 2005. Natl Vital Stat Rep. 2008;56:1-120.
2. Gauthier S, Reisberg B, Zaudig M, et al. Mild cognitive impairment. Lancet. 2006;367:1262-1270.
3. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984;34:939-944. (Pubitemid 14076461)
4. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathological assessment of Alzheimer's disease. Neurology. 1991;41:479-486.
5. Selkoe DJ. Alzheimer's disease: genotypes, phenotypes, and treatments. Science. 1997;275:630-631. (Pubitemid 27061322)
6. Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical"Alzheimer's disease. Ann Neurol. 1999;45:358-368. (Pubitemid 29120041)
7. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review) - report of the Quality StandardsSubcommittee of the American Academy of Neurology. Neurology. 2001;56: 1143-1153. (Pubitemid 32405708)
8. DSM-IIIR. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed., revised. Washington, DC: American Psychiatric Association; 1987.
9. Lim A, Tsuang D, Kukull W, et al. Clinico-neuropathological correlation of Alzheimer's disease in a community-based case series. J Am Geriatr Soc. 1999; 47:564-569. (Pubitemid 29215585)
10. Jobst KA, Barnetson LP, Shepstone BJ. Accurate prediction of histologically confirmed Alzheimer's disease and the differential diagnosis of dementia: the use of NINCDS-ADRDA and DSM-III-R criteria, SPECT, x-ray CT, and Apo E4 in medial temporal lobe dementias. Oxford Project to Investigate Memory and Aging. Int Psychogeriatr. 1998;10:271-302. (Pubitemid 28470188)
11. Galasko D, Hansen LA, Katzman R, et al. Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Arch Neurol. 1994;51:888-895. (Pubitemid 24286043)
12. Massoud F, Devi G, Stern Y, et al. A clinicopathological comparison of community- based and clinic-based cohorts of patients with dementia. Arch Neurol. 1999;56:1368-1373. (Pubitemid 29519853)
13. Löppönen M, Raiha I, Isoaho R, Vahlberg T, Kivela SL. Diagnosing cognitive impairment and dementia in primary health care: a more active approach is needed. Age Ageing. 2003;32:606-612. (Pubitemid 37461568)
14. Storandt M, Morris JC. Ascertainment bias in the clinical diagnosis of Alzheimer disease. Arch Neurol. 2010;67:1364-1369.
15. 18F-FDG and PiB PET in cognitive impairment. J Nucl Med. 2009;50:878-886.
16. Foster NL, Heidebrink JL, Clark CM, et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain. 2007; 130:2616-2635. (Pubitemid 47511706)
17. Herholz K, Nordberg A, Salmon E, et al. Impairment of neocortical metabolism predicts progression in Alzheimer's disease. Dement Geriatr Cogn Disord. 1999; 10:494-504. (Pubitemid 29512018)
18. Kuhl DE. Imaging local brain function with emission computed tomography. Radiology. 1984;150:625-631. (Pubitemid 14190549)
19. Sokoloff L. Relation between physiological function and energy metabolism in the central nervous system. J Neurochem. 1977;29:13-26. (Pubitemid 8150483)
20. Liu X, Erikson C, Brun A. Cortical synaptic changes and gliosis in normal aging, Alzheimer's disease and frontal lobe degeneration. Dementia. 1996;7:128-134.
21. Minoshima S, Foster NL, Kuhl DE. Posterior cingulate cortex in Alzheimer's disease. Lancet. 1994;344:895. (Pubitemid 24290409)
22. Foster NL, Chase TN, Mansi L, et al. Cortical abnormalities in Alzheimer's disease. Ann Neurol. 1984;16:649-654. (Pubitemid 15177667)
23. Kuhl DE, Metter J, Benson DF, et al. Similarities in cerebral glucose metabolism in Alzheimer's and parkinsonian dementia. J Cereb Blood Flow Metab. 1985;5 (suppl 1):S169-S170.
24. Friedland RP, Brun A, Budinger TF. Pathological and positron emission tomographic correlations in Alzheimer's disease [letter]. Lancet. 1985;1:228. (Pubitemid 15151499)
25. Mielke R, Schroder R, Fink GR, Kessler J, Herholz K, Heis WD. Regional cerebral glucose metabolism and postmortem pathology in Alzheimer's disease. Acta Neuropathol. 1996;91:174-179. (Pubitemid 26021405)
26. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol. 1997;42:85-94. (Pubitemid 27304784)
27. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the e4 allele for apolipoprotein E. N Engl J Med. 1996;334:752-758. (Pubitemid 26089356)
28. Womack KB, Diaz-Arrastia R, Aizenstein HJ, et al. Temporoparietal hypometabolism in frontotemporal lobar degeneration and associated imaging diagnostic errors. Arch Neurol. 2011;68:329-337.
29. Weaver JD, Espinoza R, Weintraub NT. The utility of PET brain imaging in the initial evaluation of dementia. J Am Med Dir Assoc. 2007;8:150-157. (Pubitemid 46344868)
30. Mielke R, Heiss WD. Positron emission tomography for diagnosis of Alzheimer's disease and vascular dementia. J Neural Transm Suppl. 1998;53:237-250. (Pubitemid 28361784)
31. Herholz K, Schopphoff H, Schmidt M, et al. Direct comparison of spatially normalized PET and SPECT scans in Alzheimer's disease. J Nucl Med. 2002;43:21-26. (Pubitemid 34101183)
32. Gill SS, Rochon PA, Guttman M, Laupacis A. The value of positron emission tomography in the clinical evaluation of dementia. J Am Geriatr Soc. 2003;51: 258-264. (Pubitemid 36205857)
33. Patwardhan MB, McCrory DC, Matchar DB, Samsa GP, Rutschmann OT. Alzheimer disease: operating characteristics of PET - a meta-analysis. Radiology. 2004;231:73-80. (Pubitemid 38375412)
34. Döbert N, Pantel J, Frolich L, Hamscho N, Menzel C, Grunwald F. Diagnostic value of FDG-PET and HMPAO-SPET in patients with mild dementia and mild cognitive impairment: metabolic index and perfusion index. Dement Geriatr Cogn Disord. 2005;20:63-70. (Pubitemid 41191618)
35. Panegyres PK, Rogers JM, McCarthy M, Campbell A, Wu JS. Fluorodeoxyglucose- positron emission tomography in the differential diagnosis of early-onset dementia: a prospective, community-based study. BMC Neurol. 2009;9:41.
36. Varma AR, Snowden JS, Lloyd JJ, Talbot PR, Mann DM, Neary D. Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer's disease and frontotemporal dementia. J Neurol Neurosurg Psychiatry. 1999;66:184-188. (Pubitemid 29103519)
37. Mendez M, Perryman K, Patton R, FreyW. Alzheimer's disease with and without the neuropathology of Parkinson's disease: clinical and epidemiological differences [abstract]. Neurology. 1998;50(suppl 4):A281.
38. Burke JF, Albin RL, Koeppe RA, et al. Assessment of mild dementia with amyloid and dopamine terminal positron emission tomography. Brain. 2011;134:1647-1657.
39. Jagust W, Reed B, Mungas D, Ellis W, Decarli C. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology. 2007;69:871-877. (Pubitemid 47329586)
40. Hoffman JM, Welsh-Bohmer KA, Hanson M, et al. FDG PET imaging in patients with pathologically verified dementia. J Nucl Med. 2000;41:1920-1928.
41. Minoshima S, Foster NL, Sima AA, Frey KA, Albin RL, Kuhl DE. Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol. 2001;50:358-365. (Pubitemid 32848738)
42. Silverman DH, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA. 2001;286:2120-2127. (Pubitemid 34041597)
43. Mosconi L, Mistur R, Switalski R, et al. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2009;36:811-822.
44. Albin RL, Minoshima S, D'Amato CJ, Frey KA, Kuhl DE, Sima AAF. Fluorodeoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology. 1996;47:462-466. (Pubitemid 26324044)
45. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65:1863-1872. (Pubitemid 43970103)
46. Luis CA, Barker WW, Gajaraj K, et al. Sensitivity and specificity of three clinical criteria for dementia with Lewy bodies in an autopsy-verified sample. Int J Geriatr Psychiatry. 1999;14:526-533. (Pubitemid 29366637)
47. McKeith IG, Ballard CG, Perry RH, et al. Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology. 2000;54:1050-1058. (Pubitemid 30151844)
48. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546-1554.
49. Hodges JR, Patterson K, Oxbury S, Funnell E. Semantic dementia: progressive fluent aphasia with temporal lobe atrophy. Brain. 1992;115:1783-1806. (Pubitemid 23054865)
50. Friedland RP, Koss E, Lerner A, et al. Functional imaging, the frontal lobes, and dementia. Dementia. 1993;4:192-203. (Pubitemid 23234434)
51. Diehl-Schmid J, Grimmer T, Drzezga A, et al. Decline of cerebral glucose metabolism in frontotemporal dementia: a longitudinal 18F-FDG-PET-study. Neurobiol Aging. 2007;28:42-50. (Pubitemid 44791637)
52. 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med. 2008;49:390-398.
53. Ishii K, Sakamoto S, Sasaki M, et al. Cerebral glucose metabolism in patients with frontotemporal dementia. J Nucl Med. 1998;39:1875-1878. (Pubitemid 28518885)
54. Jeong Y, Park KC, Cho SS, et al. Pattern of glucose hypometabolism in frontotemporal dementia with motor neuron disease. Neurology. 2005;64:734-736. (Pubitemid 40261911)
55. Diehl-Schmid J, Grimmer T, Drzezga A, et al. Longitudinal changes of cerebral glucose metabolism in semantic dementia. Dement Geriatr Cogn Disord. 2006; 22:346-351. (Pubitemid 44651450)
56. Laforce R Jr, Buteau JP, Paquet N, Verret L, Houde M, Bouchard RW. The value of PET in mild cognitive impairment, typical and atypical/unclear dementias: a retrospective memory clinic study. Am J Alzheimers Dis Other Demen. 2010; 25:324-332.
57. Li Y, Rinne JO, Mosconi L, et al. Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2008;35:2169-2181.
58. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med. 1995;36:1238-1248.
59. Friston K, Holmes A, Worsley K, Poline J-B, Frith C, Frackowiak R. Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp. 1995;2:189-210. (Pubitemid 124008664)
60. Herholz K, Salmon E, Perani D, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage. 2002;17:302-316.
61. Ball MJ, Fisman M, Hachinski V, et al. A new definition of Alzheimer's disease: a hippocampal dementia. Lancet. 1985;1:14-16. (Pubitemid 15160543)
62. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239-259.
63. Braak H, Braak E. Development of Alzheimer-related neurofibrillary changes in the neocortex inversely recapitulates cortical myelogenesis. Acta Neuropathol. 1996;92:197-201. (Pubitemid 26248463)
64. Landau SM, Harvey D, Madison CM, et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging. 2011;32:1207-1218.
65. Chen K, Langbaum JB, Fleisher AS, et al. Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: findings from the Alzheimer's Disease Neuroimaging Initiative. Neuroimage. 2010;51:654-664.
66. Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 2010;9:1118-1127.
67. Hampel H, Frank R, Broich K, et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov. 2010;9: 560-574.
68. Garraux G, Salmon E, Degueldre C, Lemaire C, Franck G. Medial temporal lobe metabolic impairment in dementia associated with motor neuron disease. J Neurol Sci. 1999;168:145-150. (Pubitemid 29467434)
69. Franceschi M, Anchisi D, Pelati O, et al. Glucose metabolism and serotonin receptors in the frontotemporal lobe degeneration. Ann Neurol. 2005;57: 216-225. (Pubitemid 40179860)
70. Schwartz WJ, Smith CB, Davidsen L, et al. Metabolic mapping of functional activity in the hypothalamo-neurohypophysial system of the rat. Science. 1979; 205:723-725. (Pubitemid 9253867)
71. Magistretti PJ, Pellerin L. Cellular mechanisms of brain energy metabolism and their relevance to functional brain imaging. Philos Trans R Soc Lond B Biol Sci. 1999;354:1155-1163. (Pubitemid 29400898)
72. Magistretti PJ. Neuron-glia metabolic coupling and plasticity. J Exp Biol. 2006; 209:2304-2311. (Pubitemid 44065524)
73. Piert M, Koeppe RA, Giordani B, Berent S, Kuhl DE. Diminished glucose transport and phosphorylation in Alzheimer's disease determined by dynamic FDGPET. J Nucl Med. 1996;37:201-208. (Pubitemid 26150890)
74. Mark RJ, Pang Z, Geddes JW, Uchida K, Mattson MP. Amyloid beta-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation. J Neurosci. 1997;17:1046-1054. (Pubitemid 27043963)
75. Yakushev I, Schreckenberger M, Müller MJ, et al. Functional implications of hippocampal degeneration in early Alzheimer's disease: a combined DTI and PET study. Eur J Nucl Med Mol Imaging. 2011;38:2219-2227.
76. Minoshima S, Cross DJ, Foster NL, Henry TR, Kuhl DE. Discordance between traditional pathologic and energy metabolic changes in very early Alzheimer's disease: pathophysiological implications. Ann N Y Acad Sci. 1999;893:350-352. (Pubitemid 30038102)
77. Liang WS, Reiman EM, Valla J, et al. Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons. Proc Natl Acad Sci USA. 2008;105:4441-4446. (Pubitemid 351754399)
78. Paulus W, Bancher C, Jellinger K. Interrater reliability in the neuropathologic diagnosis of Alzheimer's disease. Neurology. 1992;42:329-332.
79. Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol. 2009; 66:200-208.
80. Kovacs GG, Alafuzoff I, Al-Sarraj S, et al. Mixed brain pathologies in dementia: the BrainNet Europe consortium experience. Dement Geriatr Cogn Disord. 2008;26:343-350.
81. Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008; 65:1509-1517.
82. Sunderland T, Linker G, Mirza N, et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA. 2003;289:2094-2103. (Pubitemid 37430211)
83. Jack CR Jr, Petersen RC, O'Brien PC, Tangalos EG. MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease. Neurology. 1992;42:183-188.
84. Klunk WE, Engler E, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease using the novel positron emission tomography tracer, Pittsburgh Compound- B. Ann Neurol. 2004;55:306-319. (Pubitemid 38269583)
85. Lo RY, Hubbard AE, Shaw LM, et al. Longitudinal change of biomarkers in cognitive decline. Arch Neurol. 2011;68:1257-1266.
86. Petrie EC, Cross DJ, Galasko D, et al. Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings. Arch Neurol. 2009;66:632-637.
87. Lucignani G, Nobili F. FDG-PET for early assessment of Alzheimer's disease: isn't the evidence base large enough? Eur J Nucl Med Mol Imaging. 2010;37: 1604-1609.
88. 18F-FDG PET database of longitudinally confirmed healthy elderly individuals improves detection of mild cognitive impairment and Alzheimer's disease. J Nucl Med. 2007;48:1129-1134.
89. Silverman DH, Mosconi L, Ercoli L, Chen W, Small GW. Positron emission tomography scans obtained for the evaluation of cognitive dysfunction. Semin Nucl Med. 2008;38:251-261. (Pubitemid 351726326)
90. McMurtray AM, Licht E, Yeo T, Krisztal E, Saul RE, Mendez MF. Positron emission tomography facilitates diagnosis of early-onset Alzheimer's disease. Eur Neurol. 2008;59:31-37. (Pubitemid 350277257)
91. Medicare National Coverage Determinations Manual: Chapter 1, Part 4 (Sections 200-310.1)-Coverage Determinations. Centers for Medicare and Medicaid Services Web site. Available at: http://www.cms.gov/manuals/downloads/ ncd103c1-Part4.pdf. Accessed November 21, 2011.
92. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging- Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263-269.
93. Consensus report of the working group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol Aging. 1998;19:109-116.
94. 18F-FDG PET for detection of Alzheimer's disease. J Nucl Med. 2007;48:547-552.
95. Chen WP, Samuraki M, Yanase D, et al. Effect of sample size for normal database on diagnostic performance of brain FDG PET for the detection of Alzheimer's disease using automated image analysis. Nucl Med Commun. 2008;29:270-276. (Pubitemid 351499304)